Table 2 Prior treatment (ITT population)

From: Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

 

High risk

Standard risk

Unknown/missing

 

Kd (n=97)

Vd (n=113)

Kd (n=284)

Vd (n=291)

Kd (n=83)

Vd (n=61)

Number of prior regimens, a n (%)

 1

44 (45.4)

53 (46.9)

149 (52.5)

144 (49.5)

39 (47.0)

35 (57.4)

 2

37 (38.1)

37 (32.7)

86 (30.3)

95 (32.6)

34 (41.0)

13 (21.3)

 3

16 (16.5)

22 (19.5)

49 (17.3)

52 (17.9)

10 (12.0)

13 (21.3)

Prior therapy, n (%)

 Bortezomib

54 (55.7)

61 (54.0)

150 (52.8)

158 (54.3)

46 (55.4)

33 (54.1)

 Carfilzomib

0

0

1 (0.4)

0

1 (1.2)

1 (1.6)

 Lenalidomide

43 (44.3)

51 (45.1)

100 (35.2)

104 (35.7)

34 (41.0)

22 (36.1)

 Thalidomide

47 (48.5)

62 (54.9)

126 (44.4)

152 (52.2)

38 (45.8)

33 (54.1)

  1. Abbreviations: ITT, intention-to-treat; Kd, carfilzomib and dexamethasone; Vd, bortezomib and dexamethasone.
  2. aOne patient in the bortezomib group (high risk) had four prior regimens.
Back to article page